Safety of Hib-MenCY-TT Vaccine Versus Licensed Hib Conjugate Vaccine, Given at 12 to 15 Months of Age.

Number of Subjects Reporting Serious Adverse Events (SAEs)

SAEs assessed include medical occurrences that results in death, are life threatening, require hospitalization or prolongation of hospitalization, results in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subjects.

Time frame: From fourth dose up to Day 30 after fourth dose vaccination (from study Month 10-13 up to study Month 11-14)

Number of Subjects Reporting New Onset of Chronic Illnesses (NOCIs)

NOCIs include autoimmune disorders, asthma, type I diabetes, allergies.

Time frame: From fourth dose up to Day 30 after fourth dose vaccination (from study Month 10-13 up to study Month 11-14)

Number of Subjects Reporting Rash

Rash assessed was hives, idiopathic thrombocytopenic purpura, petechiae

Time frame: From fourth dose up to Day 30 after fourth dose vaccination (from study Month 10-13 up to study Month 11-14)

Number of Subjects Reporting Adverse Events Resulting in Emergency Room (ER) Visits

Time frame: From fourth dose up to Day 30 after fourth dose vaccination (from study Month 10-13 up to study Month 11-14)

Number of Subjects With Serious Adverse Events (SAEs)

SAEs assessed include medical occurrences that results in death, are life threatening, require hospitalization or prolongation of hospitalization, results in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subjects.

Time frame: From fourth dose through the end of the 6-month safety follow-up of the fourth dose phase (from study Month 10-13 up to study Month 16-19)

Number of Subjects With New Onset of Chronic Illnesses (NOCIs)

NOCIs include autoimmune disorders, asthma, type I diabetes, allergies.

Time frame: From fourth dose through the end of the 6-month safety follow-up of the fourth dose phase (from study Month 10-13 up to study Month 16-19)

Number of Subjects With Rash

Rash assessed was hives, idiopathic thrombocytopenic purpura, petechiae

Time frame: From fourth dose through the end of the 6-month safety follow-up of the fourth dose phase (from study Month 10-13 up to study Month 16-19)

Number of Subjects With Adverse Events Resulting in Emergency Room (ER) Visits

Time frame: From fourth dose through the end of the 6-month safety follow-up of the fourth dose phase (from study Month 10-13 up to study Month 16-19)